Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...

Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J's ...

Immunotherapy that blocks microglial Fcγ receptors prevents dopaminergic neuron loss in Parkinson’s disease, revealing a potential new strategy.

Lausanne, Switzerland, December 15, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ...

It aims at advancing the understanding of the biology and immunology that underscores the utility of antibodies as diagnostics and therapeutics. Monoclonal Antibodies in Immunodiagnosis and ...

Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054 demonstrated that two different active immunotherapy formulations against the same target can induce a differential ...

A new study from Washington University School of Medicine in St. Louis suggests that a type of immunotherapy—similar to that approved by the Food and Drug Administration (FDA) to treat inflammatory ...

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE study enrolling well and expanding to sites ...